Effects over time of two platelet gel supernatants on growth factor, cytokine and hyaluronan concentrations in normal synovial membrane explants challenged with lipopolysaccharide Pathophysiology of musculoskeletal disorders

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Ríos, Diana L ^a   López, Catalina ^a   Álvarez, María E ^a   Samudio, Ismael J ^b   Carmona, Jorge U ^a  

^a UNIVERSIDAD DE CALDAS   (Colombia)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CULTURE MEDIUM; GEL; SIGNAL PEPTIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; HORSE; IN VITRO STUDY; LEUKOCYTE AND PLATELET RICH GEL SUPERNATANT; LEUKOCYTE COUNT; NONHUMAN; PLATELET GEL SUPERNATANT; PROTEIN DEGRADATION; PURE PLATELET RICH GEL SUPERNATANT; SYNOVIAL FLUID LEVEL; SYNOVIUM; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; TISSUE CULTURE; ANIMAL; CELL FRACTIONATION; CULTURE MEDIUM; DRUG EFFECTS; GEL; IMMUNOLOGY; LEUKOCYTE; METABOLISM; SYNOVIAL FLUID; THROMBOCYTE; TIME FACTOR; TISSUE CULTURE TECHNIQUE;

ANIMALS; BLOOD PLATELETS; CELL FRACTIONATION; CULTURE MEDIA; CYTOKINES; GELS; HORSES; HYALURONIC ACID; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES; LIPOPOLYSACCHARIDES; PLATELET-RICH PLASMA; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; TIME FACTORS; TISSUE CULTURE TECHNIQUES;

EID: 84935024537     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0605-3     Document Type: Article

References (53)

1. Abhishek A, Doherty M. Diagnosis and clinical presentation of osteoarthritis. Rheum Dis Clin North Am. 2013;39(1):45-66.
2. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013;5(2):77-94.
3. Sofat N, Beith I, Anilkumar PG, Mitchell P. Recent clinical evidence for the treatment of osteoarthritis: what we have learned. Rev Recent Clin Trials. 2011;6(2):114-26.
4. Filardo G, Kon E, Di Martino A, Di Matteo B, Merli ML, Cenacchi A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229.
5. Filardo G, Kon E, Roffi A, Di Matteo B, Merli ML, Marcacci M. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg Sports Traumatol Arthrosc 2013: doi: 10.1007/s00167-00013-02743-00161.
6. Andia I, Abate M. Knee osteoarthritis: Hyaluronic acid, platelet-rich plasma or both in association? Expert Opin Biol Ther. 2014;14(5):635-49.
7. Wang-Saegusa A, Cugat R, Ares O, Seijas R, Cuscó X, Garcia-Balletbó M. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Arch Orthop Trauma Surg. 2011;131(3):311-7.
8. Carmona JU, Argüelles D, Climent F, Prades M. Autologous platelet concentrates as a treatment of horses with osteoarthritis: a preliminary pilot clinical study. J Equine Vet Sci. 2007;27(4):167-70.
9. Pichereau F, Décory M, Cuevas Ramos G. Autologous platelet concentrate as a treatment for horses with refractory fetlock osteoarthritis. J Equine Vet Sci. 2014;34(4):489-93.
10. Silva RF, Carmona JU, Rezende CMF. Intra-articular injections of autologous platelet concentrates in dogs with surgical reparation of cranial cruciate ligament rupture. Vet Comp Orthop Traumatol. 2013;26(4):285-90.
11. Kisiday JD, McIlwraith CW, Rodkey WG, Frisbie DD, Steadman JR. Effects of platelet-rich plasma composition on anabolic and catabolic activities in equine cartilage and meniscal explants. Cartilage. 2012;3(3):245-54.
12. Van Buul GM, Koevoet WLM, Kops N, Bos PK, Verhaar JAN, Weinans H, et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med. 2011;39(11):2362-70.
13. Amrichová J, Špaková T, Rosocha J, Harvanová D, Bačenková D, Lacko M, et al. Effect of PRP and PPP on proliferation and migration of human chondrocytes and synoviocytes in vitro. Central Eur J Biol. 2014;9(2):139-48.
14. Sundman EA, Cole BJ, Karas V, Della Valle C, Tetreault MW, Mohammed HO, et al. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med. 2014;42(1):35-41.
15. Anitua E, Sánchez M, Nurden AT, Zalduendo MM, De la Fuente M, Azofra J, et al. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology. 2007;46(12):1769-72.
16. Lippross S, Moeller B, Haas H, Tohidnezhad M, Steubesand N, Wruck CJ, et al. Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis Rheum. 2011;63(11):3344-53.
17. Mastrangelo AN, Vavken P, Fleming BC, Harrison SL, Murray MM. Reduced platelet concentration does not harm PRP effectiveness for ACL repair in a porcine in vivo model. J Orthop Res. 2011;29(7):1002-7.
18. Textor JA, Willits NH, Tablin F. Synovial fluid growth factor and cytokine concentrations after intra-articular injection of a platelet-rich product in horses. Vet J. 2013;198(1):217-23.
19. Fortier LA, Barker JU, Strauss EJ, McCarrel TM, Cole BJ. The role of growth factors in cartilage repair. Clin Orthop Relat Res. 2011;469(10):2706-15.
20. Chang KV, Hung CY, Aliwarga F, Wang TG, Han DS, Chen WS. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2014;95(3):562-75.
21. Cavallo C, Filardo G, Mariani E, Kon E, Marcacci M, Pereira Ruiz MT, et al. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am. 2014;96(5):423-9.
22. Carmona JU, López C, Sandoval JA. Review of the currently available systems to obtain platelet related products to treat equine musculoskeletal injuries. Rec Pat Reg Med. 2013;3(2):148-59.
23. Dohan Ehrenfest DM, Bielecki T, Mishra A, Borzini P, Inchingolo F, Sammartino G, et al. In search of a consensus terminology in the field of platelet concentrates for surgical use: Platelet-Rich Plasma (PRP), Platelet-Rich Fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol. 2012;13(7):1131-7.
24. McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am. 2012;94(19):e143.141-8.
25. Boswell SG, Schnabel LV, Mohammed HO, Sundman EA, Minas T, Fortier LA. Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons. Am J Sports Med. 2014;42(1):42-9.
26. Braun HJ, Kim HJ, Chu CR, Dragoo JL. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: Implications for intra-articular injury and therapy. Am J Sports Med. 2014;42(5):1204-10.
27. Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy - future or trend? Arthritis Res Ther. 2012;14(4):219.
28. Giraldo CE, López C, Álvarez ME, Samudio IJ, Prades M, Carmona JU. Effects of the breed, sex and age on cellular content and growth factor release from equine pure-platelet rich plasma and pure-platelet rich gel. BMC Vet Res. 2013;9:29.
29. Argüelles D, Carmona JU, Pastor J, Iborra A, Viñals L, Martínez P, et al. Evaluation of single and double centrifugation tube methods for concentrating equine platelets. Res Vet Sci. 2006;81(2):237-45.
30. Moses VS, Hardy J, Bertone AL, Weisbrode SE. Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants. Am J Vet Res. 2001;62(1):54-60.
31. Donnelly BP, Nixon AJ, Haupt JL. Nucleotide structure of equine platelet-derived growth factor-A and -B and expression in horses with induced acute tendinitis. Am J Vet Res. 2006;67(7):1218-25.
32. Penha-Goncalves MN, Onions DE, Nicolson L. Cloning and sequencing of equine transforming growth factor-beta 1 (TGFβ-1) cDNA. DNA Seq. 1997;7(6):375-8.
33. Civinini R, Nistri L, Martini C, Redl B, Ristori G, Innocenti M. Growth factors in the treatment of early osteoarthritis. Clin Cases Min Bone Metab. 2013;10(1):26-9.
34. Miller RE, Miller RJ, Malfait A-M. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014;70(2):185-93.
35. Eder L, Thavaneswaran A, Chandran V, Gladman DD. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis. 2014;73(6):1007-11.
36. Kamm JL, Nixon AJ, Witte TH. Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi. Equine Vet J. 2010;42(8):693-9.
37. Carmona JU, Prades M. Pathophisiology of osteoarthritis. Comp Equine. 2009;4(1):28-40.
38. Fernandes JC, Martel-Pelletier J, Pelletier J-P. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1):237-46.
39. Yang KGA, Raijmakers NJH, van Arkel ERA, Caron JJ, Rijk PC, Willems WJ, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage. 2008;16(4):498-505.
40. Millward-Sadler SJ, Wright MO, Davies LW, Nuki G, Salter DM. Mechanotransduction via integrins and interleukin-4 results in altered aggrecan and matrix metalloproteinase 3 gene expression in normal, but not osteoarthritic, human articular chondrocytes. Arthritis Rheum. 2000;43(9):2091-9.
41. Lee S-G, Lee E-J, Park W-D, Kim J-B, Kim E-O, Choi S-W. Anti-inflammatory and anti-osteoarthritis effects of fermented Achyranthes japonica Nakai. J Ethnopharmacol. 2012;142(3):634-41.
42. Furman BD, Mangiapani DS, Zeitler E, Bailey KN, Horne PH, Huebner JL, et al. Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. Arthritis Res Ther. 2014;16(3):R134.
43. Malemud C. Anticytokine therapy for osteoarthritis. Drugs Aging. 2010;27(2):95-115.
44. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998;273(45):29615-25.
45. Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman III CT, et al. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage. 2012;20(4):271-8.
46. Neidhart M, Gay RE, Gay S. Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2000;43(8):1719-28.
47. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res. 2007;68(3):290-6.
48. Hyc A, Osiecka-Iwan A, Niderla-Bielinska J, Moskalewski S. Influence of LPS, TNF, TGF-β1 and IL-4 on the expression of MMPs, TIMPs and selected cytokines in rat synovial membranes incubated in vitro. Int J Mol Med. 2011;27(1):127-37.
49. Oguchi T, Ishiguro N. Differential stimulation of three forms of hyaluronan synthase by TGF-β, IL-1β, and TNF-α. Connect Tissue Res. 2004;45(4-5):197-205.
50. Alaaeddine N, Di Battista JA, Pelletier J-P, Kiansa K, Cloutier J-M, Martel-Pelletier J. Inhibition of tumor necrosis factor α-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways. Arthritis Rheum. 1999;42(4):710-8.
51. Becker T, Tohidast-Akrad M, Humpeler S, Gerlag DM, Kiener H-P, Zenz P, et al. Clock gene expression in different synovial cells of patients with rheumatoid arthritis and osteoarthritis. Acta Histochem. 2014;116(7):1199-207.
52. Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone. 2004;34(4):665-71.
53. Fortier LA, Cole BJ. Anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis: response to Andia and Maffulli. Am J Sports Med. 2014;42(6):NP32-3.